(Q38170683)

30 August 2017

title

Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa (English)

1 reference

30 August 2017

0 references

cervix uterine cancer

1 reference

3

Silvia de Sanjosé

0 references

Nathalie Broutet

series ordinal

2

object named as

Nathalie J Broutet

1 reference

30 August 2017

Peter O Adefuye

1

1 reference

30 August 2017

Lynette A Denny

series ordinal

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

1 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

31 Suppl 5

1 reference

30 August 2017

page(s)

F53-9

1 reference

Worldwide burden of cervical cancer in 2008.

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

HPV screening for cervical cancer in rural India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

HPV testing for primary cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Evaluation of alternative methods of cervical cancer screening for resource-poor settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Accuracy of visual inspection with acetic acid for cervical cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Cost-effectiveness of cervical-cancer screening in five developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

A review of clinical trials of human papillomavirus prophylactic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Human papillomavirus vaccination in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

Achieving high coverage in Rwanda's national human papillomavirus vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.070

10.1016/J.VACCINE.2012.06.070

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference